Tauriga Sciences Inc (TAUG) 0.0038 $TAUG
Tauriga Sciences, Inc. Files Its Third Fiscal Quarter 2016 Form 10Q and Continues to Report Meaningful Progress on Multiple Fronts
Marketwire Canada - Wed Aug 10, 6:30AM CDT
NEW YORK, NY--(Marketwired - Aug 10, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a life sciences technology Company, today announced that it has filed its Form 10-Q for the quarterly period ended December 31, 2015 with the Securities and Exchange Commission (the "SEC". The Company is working expeditiously to complete and file its Form 10-K for the year ended March 31, 2016 with the SEC. Once this is complete, the Company will still be required to file its Form 10-Q for the quarterly period June 30, 2016 to be deemed fully reporting under SEC regulations.
Tauriga Sciences Inc. Secures Requisite Additional Capital to Finance Auditor Engagement Through Completion of First Fiscal Quarter 2017 Audit; Period Ending June 30, 2016
Marketwire Canada - Thu Aug 04, 6:00AM CDT
NEW YORK, NY--(Marketwired - Aug 4, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company", a diversified life sciences technology Company, today announced that it has secured additional capital from an existing institutional investor in order to finance additional audit and interim reporting related work. By securing this additional tranche of capital, the Company approximates that it can finance its auditor engagement through the First Fiscal Quarter of Fiscal Year 2017 ("Q1 FY '17" or the Period ending June 30, 2016. Recall that the Company operates, from an accounting perspective, with a March 31 Fiscal Year End. The Company expects to file its Form 10Q ("Quarterly Report" for the Third Fiscal Quarter 2016 (Period: October 1, 2015 - December 31, 2015) in the near term. Subsequent to that, the Company's next filing will be its Form 10K ("Annual Report" for the Fiscal Year End 2016 (Period Ending: March 31, 2016).
Tauriga Sciences Inc. Issues Comprehensive Update to Shareholders and Reports Significant Progress on Multiple Fronts
Marketwire Canada - Wed Jun 01, 9:30AM CDT
NEW YORK, NY--(Marketwired - Jun 1, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company", a diversified life sciences technology Company, today issued a comprehensive update to shareholders which addressed a number of important Corporate goals and milestones. The Company and its Board of Directors ("Board" strongly believe that important progress is being realized on multiple fronts.
Tauriga Sciences Inc. Completes the Successful Re-Audit of Its Fiscal Year 2014 Financial Statements and Files Its Fiscal Year 2015 Form 10K; Company On Track to Regain Fully Reporting Status
Marketwire Canada - Mon May 23, 7:00AM CDT
NEW YORK, NY--(Marketwired - May 23, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company", a diversified life sciences technology Company, today announced that it has both successfully completed the re-audit of its financial statements for the fiscal year ended March 31, 2014 and on May 20, 2016 filed its delinquent Annual Report on Form 10-K for the fiscal year ended March 31, 2015 ("2015 Form 10-K".
Tauriga Sciences, Inc. Receives Notification From Federal Court That Its Trial Date Will Be January 23, 2017; Company Seeking Monetary Award(s) Exceeding $3,000,000 USD in Litigation Against Predecessor Audit Firm Cowan Gunteski & Co. P.A.
Marketwired - Wed May 11, 7:01AM CDT
NEW YORK, NY--(Marketwired - May 11, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company", a diversified life sciences technology Company, today announced that it has been notified by the Federal Court (Southern District Florida) that the Company's Trial against its predecessor audit firm, Cowan Gunteski & Co. P.A. ("Cowan Gunteski" or "Cowan", will take place on January 23, 2017 ("the Trial Date" or "the Trial". The Trial will take place at 9:00 am EST in West Palm Beach Division ("Southern District Florida" before Judge Robin L. Rosenberg. Additionally the Pretrial Conference has been set for 9:30 am EST December 07, 2016 and the Calendar Call has been set for 9:00 am EST January 18, 2017.
Tauriga Sciences Inc. Retires $135,600 USD of Its Convertible Debt
Marketwire Canada - Fri May 06, 7:00AM CDT
NEW YORK, NY--(Marketwired - May 6, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company", a diversified life sciences technology Company, today announced it has repaid and retired $135,600 USD of its convertible debt. As of today's date, the Company has less than $225,000 USD of face value convertible debt remaining on its balance sheet. The Company will prioritize the strengthening of its balance sheet as it continues to negotiate with potential acquisition target(s).
Tauriga Sciences Inc. Completes $105,500 USD Equity Private Placement With Accredited Individual Investors
Marketwired - Mon Apr 18, 7:00AM CDT
Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company", a diversified life sciences technology Company, today announced that it has completed an equity private placement for $105,500 USD to date comprised of accredited individual investors as well as one institutional investor. The terms of this private placement are as follows: $0.004 per share of common stock with a related three year warrant for 40% of each share of common stock purchased and an exercise price of $0.01 per share. The warrants require the investors to pay cash to exercise the warrants and do not allow for cashless exercise.
Tauriga Sciences Inc. Appoints Keith M. Berman PEO of Decision Diagnostics Corp. as a Member of its Board of Directors
ACCESSWIRE - Fri Apr 15, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company", a diversified life sciences technology Company, today announced that it has appointed Mr. Keith M. Berman as a member of the Company's Board of Directors ("Board". Mr. Berman will serve as an independent director and with this appointment, Tauriga's Board is now comprised of five members, four of which the Company believes qualify as independent directors under the regulations of the Securities and Exchange Commission. Currently, Mr. Berman serves as the Principal Executive Officer, Secretary and a member of the Board of Directors of Decision Diagnostics Corp. (OTC PINK: DECN) and he brings a wealth of experience in healthcare and life sciences fields.
Tauriga Sciences, Inc. to Proceed to Trial in its Ongoing Litigation Against its Predecessor Audit Firm Cowan Gunteski & Co. P.A.; Company to Seek Monetary Award(s) in Excess of $3,000,000 USD
ACCESSWIRE - Tue Mar 22, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 22, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or "the Company", a diversified life sciences technology Company, has today announced that its good faith efforts to settle its ongoing litigation with Cowan Gunteski & Co. P.A. ("Cowan Gunteski" have proven unsuccessful. Therefore the Board of Directors ("the Board" of Tauriga has unanimously agreed to proceed to trial; the case is expected to proceed in Federal District Court -- Southern District Florida (Miami, Florida) with an expectation that the venue will be challenged. The lawsuit against Cowan Gunteski was initially filed by the Company on November 4, 2015 and subsequent to that there was a lengthy mediation process. The Company is continuing to seek the assistance of independent experts, to help ascribe dollar amounts for certain damages suffered by the Company ("provable damages". At this point in time, the Company has realized out of pocket cash losses and debts (inclusive of liquidated damages) that exceed $850,000 USD. Additional potential damages include but are not limited to: inability to properly maintain Pilus Energy's Intellectual Property ("Pilus IP", the July 31, 2015 delisting of TAUG shares from OTCQB to Pink Sheets, loss of market capitalization ("market cap", loss of trading liquidity ("trading volume", and loss of substantial business opportunities. In aggregate the Company intends to seek monetary award(s), during trial, in excess of $3,000,000 USD; that figure is expected to continually increase as additional time lapses. On a positive note, Cowan Gunteski has insurance coverage for its malpractice ("insurance coverage".
Tauriga Sciences, Inc. Updates Shareholders on Status of Litigation and Efforts to Regain OTCQB Listing
ACCESSWIRE - Fri Feb 05, 6:30AM CST
NEW YORK, NY / ACCESSWIRE / February 5, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) or ("Tauriga" or the "Company", a diversified life sciences company focused on building its existing technologies and evaluating potential acquisition candidates, today provided shareholders with two important updates relating to its ongoing litigation with its predecessor audit firm Cowan Gunteski & Co. PA ("Cowan Gunteski" and its efforts to regain its status as a fully reporting OTCQB listed company. The Company is also actively evaluating potential acquisition candidate(s) in the life sciences space, should the Company be successful in its current initiatives.
Tauriga Sciences, Inc. Secures $180,000 USD in Non-Convertible Debt Financing From Singapore-Based Institutional Investor
Marketwired - Thu Oct 01, 10:45AM CDT
Tauriga Sciences, Inc. (OTC PINK: TAUG) or ("Tauriga" or the "Company", a diversified life sciences company focused on building its existing technologies and evaluating potential acquisition candidates, has today announced the completion of $180,000 USD in Non-Convertible debt financing from Singapore-based institutional investor ALTERNATIVE STRATEGY PARTNERS PTE. LTD. ("ASP". The debt carries a fixed interest rate per annum of 11.50% ("the Designated Rate" payable in full by December 23, 2015 ("the Maturity Date". Both parties have discussed the possibility of amending terms, if necessary, under the assumption that both parties mutually agree to such amendment.
Tauriga Sciences Inc. Issues Shareholder Update on Status of Company and Future Strategic Plan
Marketwired - Fri Aug 14, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company", a diversified life sciences company, is providing its shareholders with a comprehensive update on the status of the Company as well as it strategic plan for the future. The Company's Board of Directors ("Board" has met multiple times over the past weeks to address several important issues. The Company will continually issue press releases to update shareholders whenever practicable.
Tauriga Sciences, Inc. Appoints Mr. Thomas J. Graham as a Member of the Board of Directors
Marketwired - Wed Aug 05, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company", a diversified life sciences company, today announced the appointment of Mr. Thomas J. Graham as the fourth member of the Company's Board of Directors ("Board". The appointment is effective immediately and Mr. Graham will qualify as an "independent" under the rules of the Securities and Exchange Commission. In the future, Mr. Graham may also be appointed to certain committees of Board.
Tauriga Sciences Inc. Comments on the Status of Fiscal Year 2015 Form 10-K Filing
Marketwired - Fri Jul 31, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company", a diversified life sciences company, today commented about the status of its Form 10-K for the year ended March 31, 2015 (the "Form 10-K".
Tauriga Sciences Inc. Granted 7 Day Extension by OTC Markets to Maintain Listing on OTCQB Exchange
Marketwired - Wed Jul 29, 3:50PM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company", a diversified life sciences company, today announced that is has been granted a 7 calendar day extension by OTC Markets to continue trading on the OTCQB exchange despite the Company's inability to file its Form 10-K for the year ended March 31, 2015 ("Form 10-K" with the Securities and Exchange Commission ("SEC" prior to 5:30 pm EDT today, July 29, 2015. If this extension had not been granted, Tauriga's common stock would have been moved to the OTC Pink Limited Information category at open of trading Thursday, July 30, 2015.
Tauriga Sciences, Inc. Files Its Third Fiscal Quarter 2016 Form 10Q and Continues to Report Meaningful Progress on Multiple Fronts
Marketwire Canada - Wed Aug 10, 6:30AM CDT
NEW YORK, NY--(Marketwired - Aug 10, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a life sciences technology Company, today announced that it has filed its Form 10-Q for the quarterly period ended December 31, 2015 with the Securities and Exchange Commission (the "SEC". The Company is working expeditiously to complete and file its Form 10-K for the year ended March 31, 2016 with the SEC. Once this is complete, the Company will still be required to file its Form 10-Q for the quarterly period June 30, 2016 to be deemed fully reporting under SEC regulations. Tauriga Sciences Inc. Secures Requisite Additional Capital to Finance Auditor Engagement Through Completion of First Fiscal Quarter 2017 Audit; Period Ending June 30, 2016
Marketwire Canada - Thu Aug 04, 6:00AM CDT
NEW YORK, NY--(Marketwired - Aug 4, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced that it has secured additional capital from an existing institutional investor in order to finance additional audit and interim reporting related work. By securing this additional tranche of capital, the Company approximates that it can finance its auditor engagement through the First Fiscal Quarter of Fiscal Year 2017 ("Q1 FY '17" or the Period ending June 30, 2016. Recall that the Company operates, from an accounting perspective, with a March 31 Fiscal Year End. The Company expects to file its Form 10Q ("Quarterly Report" for the Third Fiscal Quarter 2016 (Period: October 1, 2015 - December 31, 2015) in the near term. Subsequent to that, the Company's next filing will be its Form 10K ("Annual Report" for the Fiscal Year End 2016 (Period Ending: March 31, 2016). Tauriga Sciences Inc. Issues Comprehensive Update to Shareholders and Reports Significant Progress on Multiple Fronts
Marketwire Canada - Wed Jun 01, 9:30AM CDT
NEW YORK, NY--(Marketwired - Jun 1, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today issued a comprehensive update to shareholders which addressed a number of important Corporate goals and milestones. The Company and its Board of Directors ("Board" strongly believe that important progress is being realized on multiple fronts. Tauriga Sciences Inc. Completes the Successful Re-Audit of Its Fiscal Year 2014 Financial Statements and Files Its Fiscal Year 2015 Form 10K; Company On Track to Regain Fully Reporting Status
Marketwire Canada - Mon May 23, 7:00AM CDT
NEW YORK, NY--(Marketwired - May 23, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced that it has both successfully completed the re-audit of its financial statements for the fiscal year ended March 31, 2014 and on May 20, 2016 filed its delinquent Annual Report on Form 10-K for the fiscal year ended March 31, 2015 ("2015 Form 10-K". Tauriga Sciences, Inc. Receives Notification From Federal Court That Its Trial Date Will Be January 23, 2017; Company Seeking Monetary Award(s) Exceeding $3,000,000 USD in Litigation Against Predecessor Audit Firm Cowan Gunteski & Co. P.A.
Marketwired - Wed May 11, 7:01AM CDT
NEW YORK, NY--(Marketwired - May 11, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced that it has been notified by the Federal Court (Southern District Florida) that the Company's Trial against its predecessor audit firm, Cowan Gunteski & Co. P.A. ("Cowan Gunteski" or "Cowan", will take place on January 23, 2017 ("the Trial Date" or "the Trial". The Trial will take place at 9:00 am EST in West Palm Beach Division ("Southern District Florida" before Judge Robin L. Rosenberg. Additionally the Pretrial Conference has been set for 9:30 am EST December 07, 2016 and the Calendar Call has been set for 9:00 am EST January 18, 2017. Tauriga Sciences Inc. Retires $135,600 USD of Its Convertible Debt
Marketwire Canada - Fri May 06, 7:00AM CDT
NEW YORK, NY--(Marketwired - May 6, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced it has repaid and retired $135,600 USD of its convertible debt. As of today's date, the Company has less than $225,000 USD of face value convertible debt remaining on its balance sheet. The Company will prioritize the strengthening of its balance sheet as it continues to negotiate with potential acquisition target(s). Tauriga Sciences Inc. Completes $105,500 USD Equity Private Placement With Accredited Individual Investors
Marketwired - Mon Apr 18, 7:00AM CDT
Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced that it has completed an equity private placement for $105,500 USD to date comprised of accredited individual investors as well as one institutional investor. The terms of this private placement are as follows: $0.004 per share of common stock with a related three year warrant for 40% of each share of common stock purchased and an exercise price of $0.01 per share. The warrants require the investors to pay cash to exercise the warrants and do not allow for cashless exercise. Tauriga Sciences Inc. Appoints Keith M. Berman PEO of Decision Diagnostics Corp. as a Member of its Board of Directors
ACCESSWIRE - Fri Apr 15, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced that it has appointed Mr. Keith M. Berman as a member of the Company's Board of Directors ("Board". Mr. Berman will serve as an independent director and with this appointment, Tauriga's Board is now comprised of five members, four of which the Company believes qualify as independent directors under the regulations of the Securities and Exchange Commission. Currently, Mr. Berman serves as the Principal Executive Officer, Secretary and a member of the Board of Directors of Decision Diagnostics Corp. (OTC PINK: DECN) and he brings a wealth of experience in healthcare and life sciences fields. Tauriga Sciences, Inc. to Proceed to Trial in its Ongoing Litigation Against its Predecessor Audit Firm Cowan Gunteski & Co. P.A.; Company to Seek Monetary Award(s) in Excess of $3,000,000 USD
ACCESSWIRE - Tue Mar 22, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 22, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or "the Company"
, a diversified life sciences technology Company, has today announced that its good faith efforts to settle its ongoing litigation with Cowan Gunteski & Co. P.A. ("Cowan Gunteski" have proven unsuccessful. Therefore the Board of Directors ("the Board" of Tauriga has unanimously agreed to proceed to trial; the case is expected to proceed in Federal District Court -- Southern District Florida (Miami, Florida) with an expectation that the venue will be challenged. The lawsuit against Cowan Gunteski was initially filed by the Company on November 4, 2015 and subsequent to that there was a lengthy mediation process. The Company is continuing to seek the assistance of independent experts, to help ascribe dollar amounts for certain damages suffered by the Company ("provable damages". At this point in time, the Company has realized out of pocket cash losses and debts (inclusive of liquidated damages) that exceed $850,000 USD. Additional potential damages include but are not limited to: inability to properly maintain Pilus Energy's Intellectual Property ("Pilus IP", the July 31, 2015 delisting of TAUG shares from OTCQB to Pink Sheets, loss of market capitalization ("market cap", loss of trading liquidity ("trading volume", and loss of substantial business opportunities. In aggregate the Company intends to seek monetary award(s), during trial, in excess of $3,000,000 USD; that figure is expected to continually increase as additional time lapses. On a positive note, Cowan Gunteski has insurance coverage for its malpractice ("insurance coverage". Tauriga Sciences, Inc. Updates Shareholders on Status of Litigation and Efforts to Regain OTCQB Listing
ACCESSWIRE - Fri Feb 05, 6:30AM CST
NEW YORK, NY / ACCESSWIRE / February 5, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company focused on building its existing technologies and evaluating potential acquisition candidates, today provided shareholders with two important updates relating to its ongoing litigation with its predecessor audit firm Cowan Gunteski & Co. PA ("Cowan Gunteski" and its efforts to regain its status as a fully reporting OTCQB listed company. The Company is also actively evaluating potential acquisition candidate(s) in the life sciences space, should the Company be successful in its current initiatives. Tauriga Sciences, Inc. Secures $180,000 USD in Non-Convertible Debt Financing From Singapore-Based Institutional Investor
Marketwired - Thu Oct 01, 10:45AM CDT
Tauriga Sciences, Inc. (OTC PINK: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company focused on building its existing technologies and evaluating potential acquisition candidates, has today announced the completion of $180,000 USD in Non-Convertible debt financing from Singapore-based institutional investor ALTERNATIVE STRATEGY PARTNERS PTE. LTD. ("ASP". The debt carries a fixed interest rate per annum of 11.50% ("the Designated Rate" payable in full by December 23, 2015 ("the Maturity Date". Both parties have discussed the possibility of amending terms, if necessary, under the assumption that both parties mutually agree to such amendment. Tauriga Sciences Inc. Issues Shareholder Update on Status of Company and Future Strategic Plan
Marketwired - Fri Aug 14, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, is providing its shareholders with a comprehensive update on the status of the Company as well as it strategic plan for the future. The Company's Board of Directors ("Board" has met multiple times over the past weeks to address several important issues. The Company will continually issue press releases to update shareholders whenever practicable. Tauriga Sciences, Inc. Appoints Mr. Thomas J. Graham as a Member of the Board of Directors
Marketwired - Wed Aug 05, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, today announced the appointment of Mr. Thomas J. Graham as the fourth member of the Company's Board of Directors ("Board". The appointment is effective immediately and Mr. Graham will qualify as an "independent" under the rules of the Securities and Exchange Commission. In the future, Mr. Graham may also be appointed to certain committees of Board. Tauriga Sciences Inc. Comments on the Status of Fiscal Year 2015 Form 10-K Filing
Marketwired - Fri Jul 31, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, today commented about the status of its Form 10-K for the year ended March 31, 2015 (the "Form 10-K". Tauriga Sciences Inc. Granted 7 Day Extension by OTC Markets to Maintain Listing on OTCQB Exchange
Marketwired - Wed Jul 29, 3:50PM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, today announced that is has been granted a 7 calendar day extension by OTC Markets to continue trading on the OTCQB exchange despite the Company's inability to file its Form 10-K for the year ended March 31, 2015 ("Form 10-K" with the Securities and Exchange Commission ("SEC" prior to 5:30 pm EDT today, July 29, 2015. If this extension had not been granted, Tauriga's common stock would have been moved to the OTC Pink Limited Information category at open of trading Thursday, July 30, 2015. 
